Annual general meeting

Whitestone REIT Board of Trustees Rejects Nomination of Two Erez Candidates

Retrieved on: 
Thursday, March 7, 2024

HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT received notice that Erez Asset Management, LLC ("Erez") has nominated two candidates to stand for election to the Board of Trustees of Whitestone REIT (the “Whitestone Board”) at the 2024 annual meeting.

Key Points: 
  • HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT received notice that Erez Asset Management, LLC ("Erez") has nominated two candidates to stand for election to the Board of Trustees of Whitestone REIT (the “Whitestone Board”) at the 2024 annual meeting.
  • The Whitestone REIT Nominating and Governance Committee (“the Committee”) has conducted a comprehensive review and evaluation of Erez candidates Bruce Schanzer and Catherine Clark.
  • Pursuant to the recommendation of the Committee, the Whitestone Board will not nominate either candidate.
  • The Whitestone Board has strong retail REIT experience, as well as experience across a full range of disciplines that enhance their oversight capabilities.

Bel Director John Tweedy to Retire from the Board and Not Stand for Re-election at the 2024 Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

The Board of Directors plans to nominate David Valletta to join the Board in 2024.

Key Points: 
  • The Board of Directors plans to nominate David Valletta to join the Board in 2024.
  • Mr. Tweedy has served on Bel’s Board since 1996 and throughout the years has served on various committees including Audit and Executive.
  • “On behalf of the Board, I thank John for his many contributions to Bel.
  • As a long-standing member of the Board, John’s insight and counsel will be missed,” said Dan Bernstein, President, CEO and Director.

CoreCivic Appoints Catherine Hernandez-Blades and Alexander R. Fischer to its Board of Directors; CoreCivic Also Announces Planned Retirement of Long-Term Board Member Donna Alvarado

Retrieved on: 
Thursday, March 7, 2024

Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.

Key Points: 
  • Both Ms. Hernandez-Blades and Mr. Fischer are expected to join various board committees in the future.
  • "We are pleased to have Catherine and Alex join our Board of Directors," said Damon Hininger, CoreCivic's President and Chief Executive Officer.
  • "Catherine brings decades of executive leadership experience in government relations, communications, and marketing in both the private and the public sectors.
  • Catherine also provides community support as a board member at several non-profits.

Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001

Retrieved on: 
Thursday, March 7, 2024

SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

Key Points: 
  • SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that updated data from its ongoing Phase I/II clinical trial of NRTX-1001, an investigational allogeneic cell therapy candidate that is being developed for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE), will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, which will be held April 13-18, 2024, in Denver, CO.

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Key Points: 
  • SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024.

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • In October 2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D.
  • Cash Position: As of December 31, 2023, Neumora had cash, cash equivalents and marketable securities of $463.8 million.
  • R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million for the same period in 2022.
  • Net Loss: The Company reported a net loss of $108.7 million for the fourth quarter of 2023, as compared to $28.1 million for the same period in 2022.

MIND CTI Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, March 6, 2024

YOQNEAM, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its fourth quarter of 2023 and its full year ended December 31, 2023.

Key Points: 
  • The following will summarize our business in the fourth quarter of 2023 and provide a more detailed review of the financial results for the quarter and for the full year.
  • Operating income of $ 1.2 million, or 21% of total revenue, compared to $1.2 million, or 23% of revenue in the fourth quarter of 2022.
  • Net income of $1.4 million, or $0.06 per share, compared to $1.3 million, or $0.06 per share in the fourth quarter of 2022.
  • Cash flow from operating activities of $0.7 million, compared to $1.4 million in the fourth quarter of 2022.

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Retrieved on: 
Tuesday, March 5, 2024

“In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.

Key Points: 
  • “In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • The company expanded its Board of Directors with the appointment of Helen Collins, MD in November 2023.
  • Cash and cash equivalents as of December 31, 2023 were $143.2 million, compared to $142.6 million at December 31, 2022.
  • During the three months ended December 31, 2023, the company used cash, cash equivalents and restricted cash of $22.9 million from operating and investing activities.

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024

SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research (AACR) 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.

Key Points: 
  • SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research (AACR) 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.
  • Dr. Hansen’s presentation “NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma” will be featured in the Major Symposium session: Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances that will be held from 10:15 -11:45 a.m. PT on Tuesday, April 9, 2024.
  • Dr. Hansen is also a featured presenter in the Educational session: Chemistry to the Clinic Part 1 of 3: Targeted Protein Degraders: Delivering Degraders to the Site of Action that will be held from 4:45 - 6:15 p.m. PT on Friday, April 5, 2024.